Clinical Policy: Idursulfase (Elaprase)

Reference Number: CP.PHAR.156
Effective Date: 02/16
Last Review Date: 02/17

Coding Implications
Revision Log

See Important Reminder at the end of this policy for important regulatory and legal information.

Description

The intent of the criteria is to ensure that patients follow selection elements established by Centene® clinical policy for idursulfase (Elaprase®).

Policy/Criteria

It is the policy of health plans affiliated with Centene Corporation® that Elaprase is **medically necessary** when the following criteria are met:

I. Initial Approval Criteria

A. Hunter Syndrome (Mucopolysaccharidosis II) (must meet all):

1. Diagnosis of Hunter syndrome confirmed by one of the following:
   a. Enzyme assay demonstrating a deficiency of iduronate 2-sulfatase activity;
   b. DNA testing.

Approval duration: 6 months

B. Other diagnoses/indications: Refer to CP.PHAR.57 - Global Biopharm Policy.

II. Continued Approval

A. Hunter Syndrome (must meet all)**:**

1. Currently receiving medication via Centene benefit or member has previously met all initial approval criteria;
2. Member is responding positively to therapy.

Approval duration: 12 months

B. Other diagnoses/indications (must meet 1 or 2)**:**

1. Currently receiving medication via Centene benefit and documentation supports positive response to therapy; or
2. Refer to CP.PHAR.57 - Global Biopharm Policy**.**

Background

Description/Mechanism of Action:

Hunter syndrome (Mucopolysaccharidosis II [MPS II]) is an X-linked recessive disease caused by insufficient levels of iduronate-2-sulfatase. This enzyme hydrolyzes the 2-sulfate esters of terminal iduronate sulfate residues from the glycosaminoglycans (GAG) dermatan sulfate and heparan sulfate in the lysosomes of various cell types. Due to the missing or defective iduronate-2- sulfatase enzyme in patients with Hunter syndrome, GAG progressively accumulates in the lysosomes of a variety of cells, leading to cellular engorgement, organomegaly, tissue

destruction, and organ system dysfunction. Elaprase is intended to provide exogenous enzyme for uptake into cellular lysosomes and subsequent catabolism of accumulated GAG.

Formulations:
Elaprase (idurslfase): Solution for reconstitution; for intravenous use
- 6 mg/3 mL vial; 2 mg/mL (46 to 74 units/mg)

FDA Approved Indications:
Elaprase is a lysosomal enzyme (idursulfase)/intravenous formulation indicated for:
- Patients with Hunter syndrome.Elaprase has been shown to improve walking capacity in patients 5 years and older.
  - In patients 16 months to 5 years of age, no data are available to demonstrate improvement in disease-related symptoms or long term clinical outcome; however, treatment with Elaprase has reduced spleen volume similarly to that of adults and children 5 years of age and older.
  - The safety and efficacy of Elaprase have not been established in pediatric patients less than 16 months of age.

Appendices
Appendix A: Abbreviation Key
GAG: Glycosaminoglycan
MPS: Mucopolysaccharidosis

Coding Implications
Codes referenced in this clinical policy are for informational purposes only. Inclusion or exclusion of any codes does not guarantee coverage. Providers should reference the most up-to-date sources of professional coding guidance prior to the submission of claims for reimbursement of covered services.

HCPCS Codes	Description
J1743	Injection, idursulfase, 1 mg

Reviews, Revisions, and Approvals	Date	Approval Date
Policy split from CP.PHAR.48. Policy converted to new template.	01/16	02/16
Age restriction removed. Allergy history is removed as the drug can be continued in some cases. Positive response to therapy added. Background section converted to new template.	12/16	02/17

References
1. Elaprase prescribing information. Lexington, MA: Shire Human Genetic Therapies, Inc.; June 2013. Available at http://www.elaprase.com. Accessed December 15, 2016.

2. Muenzer J. The mucopolysaccharidoses: A heterogeneous group of disorders with variable pediatric presentations. J Pediatr. 2004; 144(5 Suppl): S27-S34.

Important Reminder

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. "Health Plan" means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan's affiliates, as applicable.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.

This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan.

herein through the terms of their contracts. Where no such contract exists, providers, members and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services.

Note: For Medicaid members, when state Medicaid coverage provisions conflict with the coverage provisions in this clinical policy, state Medicaid coverage provisions take precedence. Please refer to the state Medicaid manual for any coverage provisions pertaining to this clinical policy.

Note: For Medicare members, to ensure consistency with the Medicare National Coverage Determinations (NCD) and Local Coverage Determinations (LCD), all applicable NCDs, LCDs and Medicare Coverage Articles should be reviewed prior to applying the criteria set forth in this clinical policy. Refer to the CMS website at http://www.cms.gov for additional information.